Sutro Biopharma, Inc. (STRO) Misses Q3 EPS by 27c
Tweet
Share
E-mailGet Alerts STRO Hot Sheet
Join SI Premium – FREE
Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q3 EPS of ($0.67), $0.27 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $9.69 million versus the consensus estimate of $10.1 million.
For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- KeyBanc Upgrades Nucor (NUE) to Overweight
- Berenberg Starts Barclays Plc (BARC:LN) (BCS) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
